-
NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials
Kwun Tong, Kowloon, HK, June 05, 2026 (GLOBE NEWSWIRE) — The newly registered 56-day exploratory study of NatureU® Mind Care BeautyU Caps — reporting within-participant changes of −46.7% in crow’s-feet wrinkle count and +58.7% in stratum corneum hydration at Day 56 — joins NatureU’s prior sleep and satiety clinical trials, both already published in peer-reviewed…
-
Zuellig Pharma Unveils State-of-the-art Clinical Trial Support Innovation Center in South Korea to Support both Domestic and Global Clinical Research Needs
Gyeonggi-Do, South Korea Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the grand opening of its new state-of-the-art Clinical Trial Support (CTS) Innovation Center in South Korea. The opening of this facility underscores Zuellig Pharma’s continued investment and commitment to advancing healthcare, reinforcing its position as a trusted regional partner in driving…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.